Opdivo Lung Cancer Approval Holds Lessons For Competitors
Executive Summary
Bristol is required to run a new study assessing the risk for pneumonitis, but analysts do not see the adverse event as a competitive threat. FDA showed significant flexibility with broad, fast approval, but Opdivo’s survival advantage may raise the bar for the rest of the class.